Green Valley Stops Global Phase III Trial of its Novel China-Approved Alzheimer’s Drug
publication date: May 16, 2022
Green Valley Pharmaceuticals has stopped the international Phase III trial for its Alzheimer’s disease treatment, citing difficulties caused by COVID and the current “funding winter” of raising capital. Green Valley’s Alzheimer’s therapy was granted a surprise China approval in 2019, the first new AD treatment in 16 years. GV-971, a product derived from seaweed, has a unique mechanism that targeted gut biota to prevent the buildup of amyloid/tau related tangles in the brain. Following China approval, Green Valley started a global five-year Phase III trial in over 2,000 people to internationalize its novel therapy. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.